Open Access Open Badges Research article

BODE-Index vs HADO-Score in Chronic Obstructive Pulmonary Disease: Which one to use in general practice?

Cristóbal Esteban1*, José M Quintana2, Javier Moraza1, Myriam Aburto1, Urko Aguirre2, José I Aguirregomoscorta1, Susana Aizpiri1, Luis V Basualdo1 and Alberto Capelastegui1

Author Affiliations

1 Pneumology Department, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain

2 Research Unit-CIBER Epidemiology and Public Health (CIBERESP), Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain

For all author emails, please log on.

BMC Medicine 2010, 8:28  doi:10.1186/1741-7015-8-28

Published: 24 May 2010



Forced expiratory volume in one second (FEV1) is used to diagnose and establish a prognosis in chronic obstructive pulmonary disease (COPD). Using multi-dimensional scores improves this predictive capacity.Two instruments, the BODE-index (Body mass index, Obstruction, Dyspnea, Exercise capacity) and the HADO-score (Health, Activity, Dyspnea, Obstruction), were compared in the prediction of mortality among COPD patients.


This is a prospective longitudinal study. During one year (2003 to 2004), 543 consecutively COPD patients were recruited in five outpatient clinics and followed for three years. The endpoints were all-causes and respiratory mortality.


In the multivariate analysis of patients with FEV1 < 50%, no significant differences were observed in all-cause or respiratory mortality across HADO categories, while significant differences were observed between patients with a lower BODE (less severe disease) and those with a higher BODE (greater severity). Among patients with FEV1 ≥ 50%, statistically significant differences were observed across HADO categories for all-cause and respiratory mortality, while differences were observed across BODE categories only in all-cause mortality.


HADO-score and BODE-index were good predictors of all-cause and respiratory mortality in the entire cohort. In patients with severe COPD (FEV1 < 50%) the BODE index was a better predictor of mortality whereas in patients with mild or moderate COPD (FEV1 ≥ 50%), the HADO-score was as good a predictor of respiratory mortality as the BODE-index. These differences suggest that the HADO-score and BODE-index could be used for different patient populations and at different healthcare levels, but can be used complementarily.